An Exploratory, Open Label, Single-arm Study to Evaluate the Effect of Eligard 6-month on Biomarkers of Disease in Patients With Metastatic Prostate Cancer
Phase of Trial: Phase IV
Latest Information Update: 15 Mar 2017
At a glance
- Drugs Leuprorelin (Primary)
- Indications Prostate cancer
- Focus Biomarker; Pharmacodynamics; Pharmacogenomic
- Acronyms EFFECT
- Sponsors Astellas Pharma Europe Ltd
- 10 Jun 2017 Biomarkers information updated
- 09 Sep 2015 Status changed from recruiting to discontinued, as reported by ClinicalTrials.gov.
- 01 Jun 2015 Planned End Date changed from 1 May 2016 to 1 Aug 2016 as reported by ClinicalTrials.gov record.